NCT04534491View on ClinicalTrials.gov

Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.

PHASE3CompletedINTERVENTIONAL
Enrollment

855

Participants

Timeline

Start Date

May 25, 2010

Primary Completion Date

June 22, 2011

Study Completion Date

June 22, 2011

Conditions
Overactive Bladder
Interventions
DRUG

Oxybutynin (Oxytrol, BAY839380)

Oxybutynin transdermal patch, 3.9 mg daily (Oxytrol Transdermal System)

Trial Locations (1)

64504

Stevenson Family Pharmacy, Saint Joseph

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY